Antibodies to Laminin β4 in Pemphigoid Diseases: Clinical-Laboratory Experience of a Single Central European Reference Centre. [PDF]
Spałek MM +6 more
europepmc +1 more source
Case Report: Dupilumab therapy for immune checkpoint inhibitor-induced bullous pemphigoid enables dual immunotherapy initiation in progressive malignant melanoma. [PDF]
Grüninger J +4 more
europepmc +1 more source
A Case of Bullous Pemphigoid Triggered by COVID-19 Infection in a Patient Receiving a Dipeptidyl Peptidase-4 Inhibitor. [PDF]
Fukata M +5 more
europepmc +1 more source
Palmoplantar-predominant bullous pemphigoid with acral purpuric lesions: An unusual presentation. [PDF]
Martínez Rozas L +3 more
europepmc +1 more source
Aberrant glycosylation patterns as potential biomarkers for diagnosis and disease progression in bullous pemphigoid. [PDF]
Miao H +7 more
europepmc +1 more source
P120 catenin is required for morphogenetic movements involved in the formation of the eyes and the cranlofacial skeleton in Xenopus [PDF]
Ciesiolka, Malgorzata +6 more
core +2 more sources
Generalised Bullous Pemphigoid in a Young Man After Exposure to Haemodialysis Membrane: A Case Report. [PDF]
Shama N, Snehal P.
europepmc +1 more source
Effective response to high-frequency and prolonged dupilumab therapy in severe refractory bullous pemphigoid: A case study. [PDF]
Jiang X +5 more
europepmc +1 more source
Super-resolution imaging detects BP180 autoantigen in immunoglobulin M pemphigoid
Bullous pemphigoid is generally caused by immunoglobulin (Ig)G autoantibodies against hemidesmosomal BP180 and/or BP230. Recently, the concept of IgM pemphigoid has been proposed. A 23-year-old Japanese woman presented with a 4-month history of severely itchy papules showing subepidermal separations with mild neutrophil infiltration.
openaire

